BioViva, founded in Bainbridge Island, Washington, is an American biotechnology company dedicated to extending healthy human lifespans through advanced gene therapy. The company's core mission is to combat aging and its associated diseases, such as heart disease, dementia, diabetes, and frailty, by utilizing Adeno-Associated Virus (AAV) and Cytomegalovirus (CMV) gene therapy. BioViva aims to revolutionize healthcare by addressing the cellular aging processes that drive these chronic ailments.
Notable figures affiliated with BioViva include its CEO, Elizabeth Parrish, who is a prominent advocate for anti-aging research. The company has garnered attention from investors interested in groundbreaking biotech innovations. Key achievements include pioneering experimental gene therapies that have shown promise in preclinical studies. BioViva's impact lies in its potential to transform the treatment of age-related diseases, offering hope for significantly improved health spans and quality of life for future generations.
